Evaluation of Diagnostic Value in Using a Panel of Multiple Tumor-Associated Antigens for Immunodiagnosis of Cancer

Table 2

Sequential addition of antigens to the miniarray of eight TAAs.

Number of different TAA panels	Number and percentage of autoantibodies in different types of cancers
	Lung (98)	HCC (50)	Colorectal (46)	Gastric (41)	Others (69)	Total (304)	NHS (58)
(1) Koc	9 (9.2)^a	9 (18.0)^b	7 (15.2)^b	2 (4.9)	8 (11.6)^a	35 (11.5)^b	0 (0)
(2) Koc and p62	20 (20.4)^b	17 (34.0)^b	15 (32.6)^b	6 (14.6)^a	15 (21.7)^b	73 (24.0)^b	1 (1.7)
(3) Koc, p62, and Imp1	31 (31.6)^b	22 (44.0)^b	20 (43.5)^b	10 (24.4)^b	18 (26.1)^b	101 (33.2)^b	1 (1.7)
(4) Koc, p62, Imp1, and cyclin B1	41 (41.8)^b	26 (52.0)^b	22 (47.8)^b	16 (39.0)^b	29 (42.0)^b	134 (44.1)^b	2 (3.4)
(5) Koc, p62, Imp1, cyclin B1, and p16	47 (48.0)^b	27 (54.0)^b	24 (52.2)^b	19 (46.3)^b	36 (52.2)^b	153 (50.3)^b	4 (6.9)
(6) Koc, p62, Imp1, cyclin B1, p16, and survivin	54 (55.1)^b	29 (58.0)^b	25 (54.3)^b	21 (51.2)^b	38 (55.1)^b	167 (55.0)^b	5 (8.6)
(7) Koc, p62, Imp1, cyclin B1, p16, survivin, and C-myc	58 (59.2)^b	32 (64.0)^b	28 (60.9)^b	23 (56.1)^b	42 (60.9)^b	183 (60.2)^b	7 (12.1)
(8) Koc, p62, Imp1, cyclin B1, p16, survivin, C-myc, and p53	63 (64.3)^b	33 (66.0)^b	30 (65.2)^b	23 (56.1)^b	44 (63.8)^b	193 (63.5)^b	8 (13.8)

All 𝑃 values relative to NHS were calculated to be <0.05 (^a) or 0.01 (^b); HCC: hepatocellular carcinoma; NHS: normal human sera.